Company / Current Assets
Gilead Sciences Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$18.3B
FY2025
5-year range
$14.4B / $19.2B
FY2021-FY2025
Trend
-4.3%
vs FY2024
Sector context
#8 of 213
Health Care
What the data says
Among 213 Health Care companies, Gilead Sciences is in the top 4% for current assets. Current Assets has fluctuated over the past 10 years, ranging from $14.4B in FY2022 to $35.8B in FY2018.
Based on SEC 10-K filings.
$18.3B in FY2025 with a 5-year CAGR of +2.8%. Top quartile in the Health Care sector.
Improved from $16.1B to $18.3B over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +8.3%
- 5-Year CAGR
- +2.8%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 213This company $18.3B Sector average $2.5B
▼
+627.1% above sector average
Key checks
Key Insights
- 5-year CAGR of +2.8%, indicating consistent growth.
- In FY2025, current assets decreased 4.3% year-over-year.
- Ranks #8 out of 213 companies in the Health Care sector.
- Peak current assets was recorded in FY2018.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.3B | -4.3% |
| FY2024 | $19.2B | +19.2% |
| FY2023 | $16.1B | +11.4% |
| FY2022 | $14.4B | -2.2% |
| FY2021 | $14.8B | -7.7% |
| FY2020 | $16.0B | -47.2% |
| FY2019 | $30.3B | -15.5% |
| FY2018 | $35.8B | +12.6% |
| FY2017 | $31.8B | +55.7% |
| FY2016 | $20.4B | -17.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026